Adamson, C.S.Chibale, K.Goss, R.J.M.Jaspars, M.Newman, D.J.Dorrington, R.A.2024-03-212024-03-212021-03-21Adamson CS, Chibale K, Goss RJM, Jaspars M, Newman DJ, Dorrington RA. Antiviral drug discovery: preparing for the next pandemic. Chemical Society Reviews. 2021;50(6):3647-55. doi: 10.1039/D0CS01118E.10.1039/D0CS01118Ehttps://pubs.rsc.org/en/content/articlelanding/2021/cs/d0cs01118ehttps://hdl.handle.net/11288/595598Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/SARS-CoV-2OutbreakAntiviral drugSDG-03 Good health and well-beingArticleChemical Society Reviews